First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424 August 9, 2018 A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer, has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells.Read more.Source: Jose Marques Lopes, PHD - Prostate Cancer News Today Prostate Cancer News
A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer, has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells.Read more.Source: Jose Marques Lopes, PHD - Prostate Cancer News Today
